When was Novigenix founded?

Novigenix was founded in 2014 and raised its 1st funding round 6 years after it was founded.

Where is Novigenix located?

Novigenix is headquartered in Epalinges, Switzerland.

How many employees does Novigenix have?

As of May 31, 2026, the latest employee count at Novigenix is 18.

Is Novigenix a funded company?

Novigenix is a funded company, having raised a total of $20M across 3 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Jan 21, 2020.

When was the latest funding round of Novigenix?

Novigenix's latest funding was a €***** Grant (prize money) round on Apr 07, 2025, with participation from 1 investor.

Where does Novigenix rank among its competitors?

Novigenix ranks 10th amongst 62 active competitors, of which 17 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Cofactor Genomics, which secured an undisclosed amount in Dec, 2025.

Who are the top competitors of Novigenix?

Novigenix's top competitors include Geneoscopy, Freenome Health and Veracyte. Among them, Cofactor Genomics secured the most recent funding round in December, 2025.

Novigenix - 2026 Company Profile, Funding & Competitors

Novigenix is a series B company based in Epalinges (Switzerland), founded in 2014. It operates as a Developer of technology for cancer precision medicine. Novigenix has raised $20M in funding. The company has 62 active competitors, including 17 funded and 8 that have exited. Its top competitors include companies like Geneoscopy, Freenome Health and Veracyte.

Company Details

Developer of technology for cancer precision medicine. It offers an Immuno-transcriptomic platform combined with machine learning and predictive algorithms that enables the identification of disease-specific mRNA signatures of immune cells and the progression of the disease. Its lead product, Colox a molecular test that measures the immune system's reaction to colorectal cancer.

Key Metrics

Founded Year

2014

Location

Epalinges, Switzerland

Stage

Series B

Total Funding

$20M in 3 rounds

Latest Funding Round

Grant (prize money), Apr 07, 2025, €*****

Investors

Europa & 1 more

Ranked

10^th among 62 active competitors

Employee Count

18 as on May 31, 2026

Investment & Acquisitions

Diagnoplex

Similar Companies

Geneoscopy & 78 more

View Novigenix's full profile

Novigenix has raised a total funding of $20M over 3 rounds. Its first funding round was on Jan 21, 2020. Its latest funding round was a Grant (prize money) round on Apr 07, 2025 for €*****. 1 investor participated in its latest round. Novigenix has 2 institutional investors.

Here is the list of recent funding rounds of Novigenix:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 07, 2025	5133667	Grant (prize money)	9292807	1518171	6027021	9378784
Nov 16, 2022	6807798	Series B	4679014	1462626	4010540	2997169
Jan 21, 2020	4018305	Grant (prize money)	1187383	4298152	4291755	Eurostars

Access funding benchmarks and valuations. Sign up today!

View details of Novigenix's funding rounds and investors

Novigenix's employee count trend

Novigenix has 18 employees as of May 26. Here is Novigenix's employee count trend over the years:

Uncover Novigenix's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Novigenix include Geneoscopy, Freenome Health and Veracyte. Here is the list of Top 10 competitors of Novigenix, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Geneoscopy 2015, St. Louis (United States), Series C	Developer of non-invasive biomarker tests for colorectal cancer	$219M	LightChain Capital, Cultivation Capital & 18 others	67/100
2nd	Freenome Health 2014, United States, Series E	Provider of a deep learning platform for detecting circulating cancer-related markers	$1.35B	Perceptive Advisors, Andreessen Horowitz ... & 65 others	66/100
3rd	Veracyte 2008, San Francisco (United States), Public	Developer of genomics-based diagnostics for cancer	$67.9M	Domain Associates, General Electric & 11 others	61/100
4th	HAYA Therapeutics 2017, Lausanne (Switzerland), Series A	Developer of RNA-based therapies for treating heart diseases	$90M	Sofinnova Partners, Humboldt Fund & 15 others	58/100
5th	Magentiq Eye 2015, Haifa (Israel), Series A	Computer vision technology in endoscopic procedures	$100K	aMoon, Neuron.VC & 10 others	55/100
6th	Cofactor Genomics 2009, San Francisco (United States), Series A	Developer of diagnostic assays using RNA sequencing	$26.2M	7percent Ventures, Menlo Ventures & 18 others	55/100
7th	Miroculus 2014, San Francisco (United States), Acquired	Developer of MicroRNA profiling platform to detect genes in the sample	$48.4M	Cota Capital, Nazca & 11 others	54/100
8th	InterVenn 2017, San Francisco (United States), Series C	Provider of an AI-based clinical decision supporting tool for cancer detection and drug development	$251M	Genoa Ventures, SoftBank Group & 12 others	54/100
9th	Alida Biosciences 2020, San Diego (United States), Series A	Provider of technology for RNA analysis to improve human health	$11.5M	Genoa Ventures, Vertical Venture Partners ... & 2 others	54/100
10th	Novigenix 2014, Epalinges (Switzerland), Series B	Developer of technology for cancer precision medicine	$20M	Europa & 1 others	52/100